Stockscreener 앱 받기
7.33
3.81%
-0.29
전일 마감가:
$7.62
열려 있는:
$7.62
하루 거래량:
86,614
Relative Volume:
0.82
시가총액:
$171.46M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-5.1986
EPS:
-1.41
순현금흐름:
$-15.54M
1주 성능:
+15.62%
1개월 성능:
+16.53%
6개월 성능:
+13.82%
1년 성능:
-27.78%
1일 변동 폭
$7.01
$7.8999
1주일 범위
$6.00
$7.99
52주 변동 폭
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.33 | 171.46M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks
Nuvectis reports promising cancer treatment results - Investing.com
Nuvectis Pharma Announces a New Publication of a Research - GlobeNewswire
Cleveland Clinic Study Confirms: Nuvectis Drug Makes Standard Lung Cancer Treatment More Effective - StockTitan
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
(NVCT) Investment Analysis and Advice - Stock Traders Daily
Nuvectis Pharma Insider Bought Shares Worth $1,200,000, According to a Recent SEC Filing - Marketscreener.com
Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma! - TipRanks
Nuvectis pharma investor acquires $1.2 million in stock By Investing.com - Investing.com
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option - Marketscreener.com
Nuvectis Pharma Announces Closing of $15.5 Million Public - GlobeNewswire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option - Yahoo Finance
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
Nuvectis Pharma launches public stock offering - MSN
Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00 - MSN
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares -February 05, 2025 at 10:52 am EST - Marketscreener.com
Nuvectis Pharma Prices of $13.5 Million Public Offering of Common Stock - citybiz
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewswire
Nuvectis pharma announces proposed public offering of common stock - MSN
Nuvectis Secures Critical $13.5M Funding: Major Push for Revolutionary Cancer Drug Development - StockTitan
Nuvectis Pharma launches public stock offering By Investing.com - Investing.com Australia
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire
Nuvectis Pharma's Strategic Funding Move: Key Details on Oncology Pipeline Investment - StockTitan
(NVCT) Trading Signals - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):